A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

PURPOSE: Although Bruton tyrosine kinase (BTK) inhibitors have demonstrated promising efficacy in patients with Waldenström macroglobulinemia (WM), data in Asian populations are scarce. This trial is the first to investigate the effect of a BTK inhibitor in Chinese patients with relapsed/refractory...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Gang, Zhou, Daobin, Cheng, Shu, Zhou, Keshu, Li, Jianyong, Zhou, Jianfeng, Xie, Liping, Jin, Jie, Zhong, Liye, Yan, Lingzhi, Guo, Haiyi, Du, Chenmu, Zhong, Jinhua, Yu, Yiling, Wu, Binghao, Qiu, Lugui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401548/
https://www.ncbi.nlm.nih.gov/pubmed/34253577
http://dx.doi.org/10.1158/1078-0432.CCR-21-0539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401548/
https://www.ncbi.nlm.nih.gov/pubmed/34253577
http://dx.doi.org/10.1158/1078-0432.CCR-21-0539

Ejemplares similares